Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
Documented progression from most recent line of therapy
Measurable disease
1 to 3 prior lines of therapy
* Subjects may be proteasome inhibitor naive or have received prior proteasome inhibitor therapy provided all the following criteria are met:
1. The subject did not discontinue any proteasome inhibitor due to intolerance or grade ≥ 3 toxicity
2. The subject is not refractory to any proteasome inhibitor, defined as progression during treatment or within 60 days after the last dose
3. The subject previously achieved a partial response (PR) or better to previous proteasome inhibitor (PI)
You may not be if
Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, or Waldenstrom's macroglobulinemia
Active plasma cell leukemia
Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C
Clareo Health | Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
